Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
Recruiting
N/A
Interventional Study
Blood Coagulation Disorder
Postoperative Blood Loss
Adverse Drug Event
Fibrinolysis; Hemorrhage
Tranexamic Acid Adverse Reaction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- University of Ioannina · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibitio…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients undergoing elective cardiac surgery using cardiopulmonary bypass
* Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines.
Exclusion Criteria:
* Age below 18 years
* Patient refusal
* Pregnancy
* End-stage renal d…
Contacts